Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Carpenter, W. T. Articles by Breier, A. F. Search for Related Content PubMed Citation Articles by Carpenter, W. T., Jr. Articles by Breier, A. F. Schizophrenia Spectrum Disorders Other Neuroleptics

Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia

OBJECTIVE: Therapeutic intervention at the earliest phase of symptom exacerbation in schizophrenia is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illness have not been established. This study examined diazepam efficacy for this phase of treatment. METHOD: A double-blind, randomized clinical trial with 53 schizophrenic patients compared diazepam with placebo (with fluphenazine treatment for a comparison group). Treatment was initiated at the earliest signs of exacerbation, and symptom progression was the dependent measure used to evaluate efficacy. RESULTS: Diazepam was statistically superior to placebo in preventing symptom progression and was comparable to fluphenazine. CONCLUSIONS: Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia. This therapeutic strategy may be especially important for patients who refuse antipsychotic drugs or as a supplemental approach in a treatment plan that emphasizes low-dose antipsychotic therapy.

This article has been cited by other articles:

				Z. J Daskalakis, B. K Christensen, P. B Fitzgerald, B. Moller, S. I Fountain, and R. Chen Increased cortical inhibition in persons with schizophrenia treated with clozapine J Psychopharmacol, March 1, 2008; 22(2): 203 - 209. [Abstract] [PDF]

				C. H. Large Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol, May 1, 2007; 21(3): 283 - 301. [Abstract] [PDF]

				L. Menzies, C. Ooi, S. Kamath, J. Suckling, P. McKenna, P. Fletcher, E. Bullmore, and C. Stephenson Effects of {gamma}-Aminobutyric Acid-Modulating Drugs on Working Memory and Brain Function in Patients With Schizophrenia Arch Gen Psychiatry, February 1, 2007; 64(2): 156 - 167. [Abstract] [Full Text] [PDF]

				B.G. Charlton Neuroleptics revisited QJM, August 1, 2006; 99(8): 561 - 561. [Full Text] [PDF]

				M. Sarter, C. L Nelson, and J. P Bruno Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia Schizophr Bull, January 1, 2005; 31(1): 117 - 138. [Abstract] [Full Text] [PDF]

				O. Freudenreich and T. A. Stern Clinical Experience With the Management of Schizophrenia in the General Hospital Psychosomatics, February 1, 2003; 44(1): 12 - 23. [Abstract] [Full Text] [PDF]

				M. I. Herz, J. S. Lamberti, J. Mintz, R. Scott, S. P. O'Dell, L. McCartan, and G. Nix A Program for Relapse Prevention in Schizophrenia: A Controlled Study Arch Gen Psychiatry, March 1, 2000; 57(3): 277 - 283. [Abstract] [Full Text] [PDF]

				C. Paton, S. Banham, and J. Whitmore Benzodiazepines in schizophrenia. Is there a trend towards long-term prescribing? Psychiatr. Bull., March 1, 2000; 24(3): 113 - 115. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us